Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter de Nully Brown

Showing results (1-10 of 101) with videos related to

Pageof 11
Sort By:
Ugeskrift for Laeger|October 14, 2005
[Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment]Peter de Nully Brown, Jesper Jurlander, Ola Lindén, et al.
European Journal of Haematology|July 5, 2007
Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphomaDorte Tholstrup, Peter de Nully Brown, Jesper Jurlander, et al.
American Journal of Hematology|March 14, 2002
Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disordersMorten Krogh Jensen, Peter de Nully Brown, Sixtus Thorsen, et al.
Blood Advances|May 13, 2026
Rituximab maintenance after first-line rituximab-bendamustineChristian Brieghel, Mikkel Werling, Peter de Nully Brown, et al.
Leukemia & Lymphoma|January 22, 2011
Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarilyDorte Tholstrup, Peter De Nully Brown, Jesper Jurlander, et al.
Pharmaceutical Medicine|January 15, 2020
Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare DatabasesTorbjörn Callréus, Tarec Christoffer El-Galaly, Mats Jerkeman, et al.
European Journal of Haematology|September 25, 2002
Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia veraMorten Krogh Jensen, Rikke Riisbro, Peter de Nully Brown, et al.
Quality Management in Health Care|September 27, 2012
Differential case reporting in a national clinical quality database: an analysis of the impact on comparison of outcome between departmentsSolvej Mårtensson, Birgitte L Frederiksen, Peter De Nully Brown, et al.
International Ophthalmology Clinics|September 25, 2025
Ocular Adnexal Natural Killer- and T-cell Lymphomas: A ReviewStine Dahl Vest, Mikkel Straarup Thagaard, Peter de Nully Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2010
Socioeconomic inequalities in prognostic markers of non-Hodgkin lymphoma: analysis of a national clinical databaseBirgitte Lidegaard Frederiksen, Peter de Nully Brown, Susanne Oksbjerg Dalton, et al.
Pageof 11

Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
Ugeskrift for Laeger|October 14, 2005
[Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment]Peter de Nully Brown, Jesper Jurlander, Ola Lindén, et al.
European Journal of Haematology|July 5, 2007
Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphomaDorte Tholstrup, Peter de Nully Brown, Jesper Jurlander, et al.
American Journal of Hematology|March 14, 2002
Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disordersMorten Krogh Jensen, Peter de Nully Brown, Sixtus Thorsen, et al.
Blood Advances|May 13, 2026
Rituximab maintenance after first-line rituximab-bendamustineChristian Brieghel, Mikkel Werling, Peter de Nully Brown, et al.
Leukemia & Lymphoma|January 22, 2011
Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarilyDorte Tholstrup, Peter De Nully Brown, Jesper Jurlander, et al.
Pharmaceutical Medicine|January 15, 2020
Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare DatabasesTorbjörn Callréus, Tarec Christoffer El-Galaly, Mats Jerkeman, et al.
European Journal of Haematology|September 25, 2002
Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia veraMorten Krogh Jensen, Rikke Riisbro, Peter de Nully Brown, et al.
Quality Management in Health Care|September 27, 2012
Differential case reporting in a national clinical quality database: an analysis of the impact on comparison of outcome between departmentsSolvej Mårtensson, Birgitte L Frederiksen, Peter De Nully Brown, et al.
International Ophthalmology Clinics|September 25, 2025
Ocular Adnexal Natural Killer- and T-cell Lymphomas: A ReviewStine Dahl Vest, Mikkel Straarup Thagaard, Peter de Nully Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2010
Socioeconomic inequalities in prognostic markers of non-Hodgkin lymphoma: analysis of a national clinical databaseBirgitte Lidegaard Frederiksen, Peter de Nully Brown, Susanne Oksbjerg Dalton, et al.
Pageof 11